181 results match your criteria mdscs mesenchymal


The Role of Tumor-Stroma Interactions in Drug Resistance Within Tumor Microenvironment.

Front Cell Dev Biol 2021 20;9:637675. Epub 2021 May 20.

Department of Biotherapy, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Collaborative Innovation Center of Biotherapy, Sichuan University, Chengdu, China.

Cancer cells resistance to various therapies remains to be a key challenge nowadays. For a long time, scientists focused on tumor cells themselves for the mechanisms of acquired drug resistance. However, recent evidence showed that tumor microenvironment (TME) is essential for regulating immune escape, drug resistance, progression and metastasis of malignant cells. Read More

View Article and Full-Text PDF

Arid5a promotes immune evasion by augmenting tryptophan metabolism and chemokine expression.

Cancer Immunol Res 2021 May 18. Epub 2021 May 18.

Laboratory of Immune regulation, World Premier International Immunology Frontier Research Center, Osaka University

The acquisition of mesenchymal traits leads to immune evasion in various cancers, but the underlying molecular mechanisms remain unclear. In this study, we found that the expression levels of AT-rich interaction domain-containing protein 5a (Arid5a), an RNA-binding protein, were substantially increased in mesenchymal tumor subtypes. The deletion of Arid5a in tumor cell lines enhanced antitumor immunity in immunocompetent mice but not in immunodeficient mice, suggesting a role for Arid5a in immune evasion. Read More

View Article and Full-Text PDF

Biological drug and drug delivery-mediated immunotherapy.

Acta Pharm Sin B 2021 Apr 31;11(4):941-960. Epub 2020 Dec 31.

Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai 200443, China.

The initiation and development of major inflammatory diseases, , cancer, vascular inflammation, and some autoimmune diseases are closely linked to the immune system. Biologics-based immunotherapy is exerting a critical role against these diseases, whereas the usage of the immunomodulators is always limited by various factors such as susceptibility to digestion by enzymes , poor penetration across biological barriers, and rapid clearance by the reticuloendothelial system. Drug delivery strategies are potent to promote their delivery. Read More

View Article and Full-Text PDF

Regulatory Immune Cells in Idiopathic Pulmonary Fibrosis: Friends or Foes?

Front Immunol 2021 22;12:663203. Epub 2021 Apr 22.

Department of Experimental and Clinical Pharmacology and Pharmacogenomics, University Hospital Tübingen, Tübingen, Germany.

The immune system is receiving increasing attention for interstitial lung diseases, as knowledge on its role in fibrosis development and response to therapies is expanding. Uncontrolled immune responses and unbalanced injury-inflammation-repair processes drive the initiation and progression of idiopathic pulmonary fibrosis. The regulatory immune system plays important roles in controlling pathogenic immune responses, regulating inflammation and modulating the transition of inflammation to fibrosis. Read More

View Article and Full-Text PDF

Epithelial-mesenchymal transition: When tumor cells meet myeloid-derived suppressor cells.

Biochim Biophys Acta Rev Cancer 2021 May 8;1876(1):188564. Epub 2021 May 8.

Department of Laboratory Medicine, the Affiliated People's Hospital, Jiangsu University, Zhenjiang, China; Department of Immunology, Jiangsu Key Laboratory of Laboratory Medicine, School of Medicine, Jiangsu University, Zhenjiang, China. Electronic address:

Myeloid-derived suppressor cells (MDSCs) are a heterogeneous myeloid cell population characterized by protumoral functions in the tumor immune network. An increasing number of studies have focused on the biological functions of MDSCs in tumor immunity. Epithelial-mesenchymal transition (EMT) is a cellular plasticity process accompanied by a loss of epithelial phenotypes and an acquisition of mesenchymal phenotypes. Read More

View Article and Full-Text PDF

Thyroid status regulates the tumor microenvironment delineating breast cancer fate.

Endocr Relat Cancer 2021 May 31;28(7):403-418. Epub 2021 May 31.

Neuroimmunomodulation and Molecular Oncology Laboratory, Institute for Biomedical Research (BIOMED), School of Medical Sciences, Pontifical Catholic University of Argentina (UCA), and the National Scientific and Technical Research Council (CONICET), Buenos Aires, Argentina.

The patient's hormonal context plays a crucial role in the outcome of cancer. However, the association between thyroid disease and breast cancer risk remains unclear. We evaluated the effect of thyroid status on breast cancer growth and dissemination in an immunocompetent mouse model. Read More

View Article and Full-Text PDF

Retinoic Acid Inhibits Tumor-Associated Mesenchymal Stromal Cell Transformation in Melanoma.

Front Cell Dev Biol 2021 6;9:658757. Epub 2021 Apr 6.

Department of Hematology, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China.

Bone marrow mesenchymal stem/stromal cells (BMSCs) can be transformed into tumor-associated MSCs (TA-MSCs) within the tumor microenvironment to facilitate tumor progression. However, the underline mechanism and potential therapeutic strategy remain unclear. Here, we explored that interleukin 17 (IL-17) cooperating with IFNγ transforms BMSCs into TA-MSCs, which promotes tumor progression by recruiting macrophages/monocytes and myeloid-derived suppressor cells (MDSCs) in murine melanoma. Read More

View Article and Full-Text PDF

Role of immune regulatory cells in breast cancer: Foe or friend?

Int Immunopharmacol 2021 Apr 14;96:107627. Epub 2021 Apr 14.

Clinical Research Institute, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou 310014, Zhejiang Province, PR China. Electronic address:

Breast cancer (BC) is the most common cancer among women between the ages of 20 and 50, affecting more than 2.1 million people and causing the annual death of more than 627,000 women worldwide. Based on the available knowledge, the immune system and its components are involved in the pathogenesis of several malignancies, including BC. Read More

View Article and Full-Text PDF

Umbilical cord mesenchymal stem cells enhance the therapeutic effect of imipenem by regulating myeloid-derived suppressor cells in septic mice.

Ann Transl Med 2021 Mar;9(5):404

School of Medicine, Southeast University, Nanjing, China.

Background: Umbilical cord mesenchymal stem cells (UC-MSCs), which possess potent immunomodulatory effects and low immunogenicity, are considered to be a promising stem cell-based therapy for sepsis. In the current study, we aimed to investigate whether the combined use of UC-MSCs and imipenem has a better effect than imipenem alone in treating ()-induced sepsis and to explore the mechanism by which UC-MSCs exert their therapeutic effect in septic mice.

Methods: We randomly divided mice into five groups with 10 mice in each group: the normal control group (control group), the sepsis group (vehicle group), the MSCs treatment group (MSCs group), the imipenem treatment group (imipenem group), and the imipenem plus MSCs treatment group (imipenem + MSCs group). Read More

View Article and Full-Text PDF

Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape.

Leukemia 2021 05 8;35(5):1229-1242. Epub 2021 Apr 8.

Paul O'Gorman Leukaemia Research Centre, College of Medical, Veterinary and Life Sciences, Institute of Cancer Sciences, University of Glasgow, Glasgow, G12 0YN, UK.

The quest for treatment-free remission (TFR) and deep molecular response (DMR) in chronic myeloid leukemia (CML) has been profoundly impacted by tyrosine kinase inhibitors (TKIs). Immunologic surveillance of residual leukemic cells is hypothesized to be one of the critical factors in successful TFR, with self-renewing leukemic stem cells implicated in relapse. Immunological characterization in CML may help to develop novel immunotherapies that specifically target residual leukemic cells upon TKI discontinuation to improve TFR rates. Read More

View Article and Full-Text PDF

Tumor Immune Microenvironment during Epithelial-Mesenchymal Transition.

Clin Cancer Res 2021 Apr 7. Epub 2021 Apr 7.

Gynecology and Obstetrics, Kyoto University Gradute School of Medicine.

Epithelial-mesenchymal transition (EMT) has been shown to play a critical role in tumor development from initiation to metastasis. EMT could be regarded as a continuum, with intermediate hybrid epithelial and mesenchymal phenotypes having high plasticity. Classical EMT is characterized by the phenotype change of epithelial cells to cells with mesenchymal properties, but EMT is also associated with multiple other molecular processes, including tumor immune evasion. Read More

View Article and Full-Text PDF

Immune evasion by cancer stem cells.

Regen Ther 2021 Jun 11;17:20-33. Epub 2021 Mar 11.

Division of Medical Genetics and Regenerative Medicine, Department of Genomic Medicine and Regenerative Therapy, Faculty of Medicine, Tottori University, 86 Nishi-cho, Yonago, Tottori, 683-8503, Japan.

Tumor immunity represents a new avenue for cancer therapy. Immune checkpoint inhibitors have successfully improved outcomes in several tumor types. In addition, currently, immune cell-based therapy is also attracting significant attention. Read More

View Article and Full-Text PDF

Role of exosomes in the immune microenvironment of ovarian cancer.

Oncol Lett 2021 May 15;21(5):377. Epub 2021 Mar 15.

Department of Gynecology, Tianjin Medical University General Hospital, Tianjin 300052, P.R. China.

Exosomes are excretory vesicles that can deliver a variety of bioactive cargo molecules to the extracellular environment. Accumulating evidence demonstrates exosome participation in intercellular communication, immune response, inflammatory response and they even play an essential role in affecting the tumor immune microenvironment. The role of exosomes in the immune microenvironment of ovarian cancer is mainly divided into suppression and stimulation. Read More

View Article and Full-Text PDF

T-cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer.

IUBMB Life 2021 May 30;73(5):726-738. Epub 2021 Mar 30.

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

The importance of the tumor microenvironment in cancer progression has been well studied for many years. Immune checkpoint inhibitors (ICIs) are regarded as potential strategies in enhancing the immune responses in patients with cancer, particularly colorectal cancer (CRC). Notably, CRCs are extraordinarily heterogeneous and mostly are microsatellite-stable (MSS) or cold tumors, which means that the immune response is not usually as strong as that of foreign cells. Read More

View Article and Full-Text PDF

TGFβ1 neutralization displays therapeutic efficacy through both an immunomodulatory and a non-immune tumor-intrinsic mechanism.

J Immunother Cancer 2021 Feb;9(2)

Ludwig Institute for Cancer Research, De Duve Institute, Brussels, Belgium

Background: Transforming growth factor-β (TGFβ) is emerging as a promising target for cancer therapy, given its ability to promote progression of advanced tumors and to suppress anti-tumor immune responses. However, TGFβ also plays multiple roles in normal tissues, particularly during organogenesis, raising toxicity concerns about TGFβ blockade. Dose-limiting cardiovascular toxicity was observed, possibly due to the blockade of all three TGFβ isoforms. Read More

View Article and Full-Text PDF
February 2021

Glutamine Deprivation Promotes the Generation and Mobilization of MDSCs by Enhancing Expression of G-CSF and GM-CSF.

Front Immunol 2020 2;11:616367. Epub 2021 Feb 2.

Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.

Solid tumors are often challenged by hypoxic and nutrient-deprived tumor microenvironments (TME) as tumors progress, due to limited perfusion and rapid nutrient consumption. While cancer cells can demonstrate the ability to survive in nutrient-deprived conditions through multiple intrinsic alterations, it is poorly understood how nutrient-deprived cancer cells co-opt the TME to promote cancer cell survival and tumor progression. In the present study, we found that glutamine deprivation markedly potentiated the expression of G-CSF and GM-CSF in mouse mammary cancer cells. Read More

View Article and Full-Text PDF
February 2021

IL-10 Signaling in the Tumor Microenvironment of Ovarian Cancer.

Adv Exp Med Biol 2021 ;1290:51-65

Wayne State University School of Medicine, Detroit, MI, USA.

Unlike other malignancies, ovarian cancer (OC) creates a complex tumor microenvironment with distinctive peritoneal ascites consisting of a mixture of several immunosuppressive cells which impair the ability of the patient's immune system to fight the disease. The poor survival rates observed in advanced stage OC patients and the lack of effective conventional therapeutic options have been attributed in large part to the immature dendritic cells (DCs), IL-10 secreting regulatory T cells, tumor-associated macrophages, myeloid-derived suppressor cells, and cancer stem cells that secrete inhibitory cytokines. This review highlights the critical role played by the intraperitoneal presence of IL-10 in the generation of an immunosuppressive tumor microenvironment. Read More

View Article and Full-Text PDF
February 2021

Epithelial-to-mesenchymal Transition Heterogeneity of Circulating Tumor Cells and Their Correlation With MDSCs and Tregs in HER2-negative Metastatic Breast Cancer Patients.

Anticancer Res 2021 Feb;41(2):661-670

Hellenic Oncology Research Group (HORG), Athens, Greece;

Background: To investigate the correlation between circulating tumor cells (CTCs) bearing cancer stem cell (CSC) and epithelial-to-mesenchymal (EMT) phenotypes and the different immunosuppressive cells in peripheral blood of patients with metastatic breast cancer (mBC).

Materials And Methods: Blood was obtained from 38 pre-treated patients with mBC before a new line of treatment. CTC detection and characterization was performed by triple immunofluorescent staining, while Myeloid-derived Suppressor Cells (MDSCs) and T regulatory cells (Tregs) were analyzed by multi-flow cytometry. Read More

View Article and Full-Text PDF
February 2021

Mechanism of tumour microenvironment in the progression and development of oral cancer.

Mol Biol Rep 2021 Feb 25;48(2):1773-1786. Epub 2021 Jan 25.

Department of Biotechnology, School of Chemical and Life Sciences, Jamia Hamdard, New Delhi, 110062, India.

Oral cancer has been a major problem all across the globe, majorly in the developing countries. With a growing emphasis in the field of cancer research, the contribution of the tumour microenvironment has been gaining a lot of importance in identifying the role of components other than the tumour cells that cause the development of cancer, thus changing the outlook. The review will shed light on the studies that describe the role of microenvironment, its components as well as summarize the studies related to their mechanism in the progression of oral cancer. Read More

View Article and Full-Text PDF
February 2021

Myeloid-derived suppressor cells promote lung cancer metastasis by CCL11 to activate ERK and AKT signaling and induce epithelial-mesenchymal transition in tumor cells.

Oncogene 2021 Feb 15;40(8):1476-1489. Epub 2021 Jan 15.

State Key Laboratory of Respiratory Disease, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.

Myeloid-derived suppressor cells (MDSCs) suppress antitumor immune activities and facilitate cancer progression. Although the concept of immunosuppressive MDSCs is well established, the mechanism that MDSCs regulate non-small cell lung cancer (NSCLC) progression through the paracrine signals is still lacking. Here, we reported that the infiltration of MDSCs within NSCLC tissues was associated with the progression of cancer status, and was positively correlated with the Patient-derived xenograft model establishment, and poor patient prognosis. Read More

View Article and Full-Text PDF
February 2021

The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment.

Bioact Mater 2021 Jul 26;6(7):1973-1987. Epub 2020 Dec 26.

Department of Ophthalmology, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai, 200011, China.

The tumor development and metastasis are closely related to the structure and function of the tumor microenvironment (TME). Recently, TME modulation strategies have attracted much attention in cancer immunotherapy. Despite the preliminary success of immunotherapeutic agents, their therapeutic effects have been restricted by the limited retention time of drugs in TME. Read More

View Article and Full-Text PDF

Mesenchymal Stem Cell Enhances the Function of MDSCs in Experimental Sjögren Syndrome.

Front Immunol 2020 22;11:604607. Epub 2020 Dec 22.

Department of Laboratory Medicine, The Affiliated People's Hospital, Jiangsu University, Zhenjiang, China.

Primary Sjögren's syndrome (pSS) is a progressive systemic autoimmune disease characterized by lymphocytic infiltrates in exocrine glands, leading to the injury of salivary and lachrymal glands. Mesenchymal stem cells (MSCs) have been demonstrated to exert great potential in the treatment of various autoimmune diseases. Although MSCs have provide an effective therapeutic approach for SS treatment, the underlying mechanisms are still elusive. Read More

View Article and Full-Text PDF
December 2020

Olfactory ecto-mesenchymal stem cell-derived exosomes ameliorate murine Sjögren's syndrome by modulating the function of myeloid-derived suppressor cells.

Cell Mol Immunol 2021 Feb 6;18(2):440-451. Epub 2021 Jan 6.

Department of Pathology and Shenzhen Institute of Research and Innovation, The University of Hong Kong; Chongqing International Institute for Immunology, Hong Kong, China.

Sjögren's syndrome (SS) is a systemic autoimmune disease characterized by progressive inflammation and tissue damage in salivary glands and lacrimal glands. Our previous studies showed that myeloid-derived suppressor cells (MDSCs) exhibited impaired immunosuppressive function during disease progression in patients with SS and mice with experimental Sjögren's syndrome (ESS), but it remains unclear whether restoring the function of MDSCs can effectively ameliorate the development of ESS. In this study, we found that murine olfactory ecto-mesenchymal stem cell-derived exosomes (OE-MSC-Exos) significantly enhanced the suppressive function of MDSCs by upregulating arginase expression and increasing ROS and NO levels. Read More

View Article and Full-Text PDF
February 2021

Role of immunotherapy in Ewing sarcoma.

J Immunother Cancer 2020 12;8(2)

Cancer Immunotherapy, Huntsman Cancer Institute, Salt Lake City, Utah, USA

Ewing sarcoma (ES) is thought to arise from mesenchymal stem cells and is the second most common bone sarcoma in pediatric patients and young adults. Given the dismal overall outcomes and very intensive therapies used, there is an urgent need to explore and develop alternative treatment modalities including immunotherapies. In this article, we provide an overview of ES biology, features of ES tumor microenvironment (TME) and review various tumor-associated antigens that can be targeted with immune-based approaches including cancer vaccines, monoclonal antibodies, T cell receptor-transduced T cells, and chimeric antigen receptor T cells. Read More

View Article and Full-Text PDF
December 2020

Porphyromonas gingivalis promotes tumor progression in esophageal squamous cell carcinoma.

Cell Oncol (Dordr) 2021 Apr 17;44(2):373-384. Epub 2020 Nov 17.

Department of Radiation Oncology, Chang Gung Memorial Hospital, Chiayi, Taiwan.

Purpose: Increasing evidence indicates that the microbiome may influence tumor growth and modulate the tumor microenvironment of gastrointestinal cancers. However, the role of oral bacteria in the development of esophageal squamous cell carcinoma (EsoSCC) has remained unclear. Herein, we investigated the relationship between the periodontal pathogen Porphyromonas gingivalis and EsoSCC. Read More

View Article and Full-Text PDF

Inhibitory effect of ginsenoside Rg3 on cancer stemness and mesenchymal transition in breast cancer via regulation of myeloid-derived suppressor cells.

PLoS One 2020 22;15(10):e0240533. Epub 2020 Oct 22.

Department of Research Center, Dongnam Institute of Radiological & Medical Sciences, Busan, Republic of Korea.

Ginsenoside Rg3 (Rg3) has been studied in several cancer models and is suggested to act through various pharmacological effects. We investigated the anticancer properties of Rg3 through myeloid-derived suppressor cell (MDSC) modulation in FM3A mouse mammary carcinoma cells. The effects of Rg3 on MDSCs and consequent changes in cancer stem-like cells (CSCs) and epithelial-mesenchymal transition (EMT) were evaluated by diverse methods. Read More

View Article and Full-Text PDF
December 2020

Nitroxoline inhibits bladder cancer progression by reversing EMT process and enhancing anti-tumor immunity.

J Cancer 2020 23;11(22):6633-6641. Epub 2020 Sep 23.

Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.

Nitroxoline is considered to be an effective treatment for the urinary tract infections. Recently, it has been found to be effective against several cancers. However, few studies have examined the anti-tumor activity of nitroxoline in bladder cancer. Read More

View Article and Full-Text PDF
September 2020

Stem cell applications in regenerative medicine for stress urinary incontinence: A review of effectiveness based on clinical trials.

Arab J Urol 2020 Apr 17;18(3):194-205. Epub 2020 Apr 17.

Department of Urology and Pediatric Urology, Universityhospital RWTH Aachen, Aachen, Germany.

Objective: To evaluate the current state, therapeutic benefit and safety of urethral injection of autologous stem cells for the treatment stress urinary incontinence (SUI).

Materials And Methods: A selective database search of PubMed, the Excerpta Medica dataBASE (EMBASE), Cochrane Library and Google Scholar was conducted to validate the effectiveness of stem cell-based therapy. The search included clinical trials published up until 4 January 2020, written in English, and included cohorts of women and men who had received stem cell-based therapy for SUI. Read More

View Article and Full-Text PDF

Splenic Hematopoietic and Stromal Cells in Cancer Progression.

Cancer Res 2021 01 30;81(1):27-34. Epub 2020 Sep 30.

Cancer Research Institute Ghent (CRIG), Ghent, Belgium.

Tumor-derived secretory factors orchestrate splenic hematopoietic and stromal cells to fuel metastasis. The spleen acts as a reservoir site for hematopoietic stem and progenitor cells, which are rapidly exploited as myeloid-derived suppressor cells at the cost of tumor-reactive lymphoid cells. Splenic erythroid progenitor cells and mesenchymal stromal cells contribute directly and indirectly to both tumor immune escape and the metastatic cascade. Read More

View Article and Full-Text PDF
January 2021

Dual Mechanisms of Novel CD73-Targeted Antibody and Antibody-Drug Conjugate in Inhibiting Lung Tumor Growth and Promoting Antitumor Immune-Effector Function.

Mol Cancer Ther 2020 Sep 17. Epub 2020 Sep 17.

Department of Pharmacology, Fudan University School of Pharmacy, Shanghai, China.

Although tyrosine kinase inhibitor therapy and immunotherapy have significantly improved lung cancer management, many patients do not benefit or become resistant to treatment, highlighting the need for novel treatments. We found elevated CD73 expression to be prevalent in non-small cell lung cancer (NSCLC) including those harboring the RAS- or RTK (EGFR, EML4-ALK) oncogenes. CD73 expression is enriched closely with the transcriptome signature of epithelial-mesenchymal transition and the immune-tolerant tumor microenvironment, which are increasingly relevant for disease progression and therapy resistance. Read More

View Article and Full-Text PDF
September 2020